Paula Alves nominated member of the IMI scientific committee


Paula Alves, CEO of iBET and Professor at ITQB NOVA University was nominated member of the Scientific Committee of the Innovative Medicines Initiative (IMI).

Created in 2008, IMI is the world's biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations) which promotes collaborations between key players in healthcare research: universities, research centers, pharmaceutical industries, SMEs, patient organisations, and medicines regulatory . Its ultimate goal is to improve health by accelerating the development of, and patient access to, innovative medicines, particularly in areas with unmet medical or social need.

With a €3.3 billion budget for the period 2014-2020 IMI aims to accelerate the discovery of next generation vaccines, medicines and treatments to provide Europeans, including the increasing numbers of older people, with more efficient and effective medicines and treatments. Greater coordination across industry sectors will result in more reliable and faster clinical trials, and better regulation.

IMI scientific committee members are top experts from a range of different fields and participate in their individual capacity. Their main role is to give strategic science-based recommendations to IMI and advice on the continued relevance of the Strategic Research Agenda and the scientific priorities and on the achievements describes annually in IMI reports.

For Paula Alves: “It is an honor for me to be nominated to the IMI Scientific Advisory Committee. It is a recognition of the high quality and international impact of our research in the development of Biopharmaceuticals and advanced therapies”